{"id":"radiotherapy-pcv-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Radiotherapy uses high-energy rays to kill cancer cells by damaging their DNA, which prevents them from reproducing. PCV chemotherapy, on the other hand, is a combination of three drugs: procarbazine, lomustine, and vincristine. These drugs work by targeting rapidly dividing cells, which are characteristic of cancer cells, and preventing them from reproducing.","oneSentence":"Radiotherapy works by damaging the DNA of cancer cells, while PCV chemotherapy targets rapidly dividing cells with a combination of drugs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:13.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT05331521","phase":"PHASE3","title":"A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2021-04-07","conditions":"Oligodendroglioma","enrollment":406},{"nctId":"NCT04702581","phase":"PHASE3","title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-07","conditions":"Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion","enrollment":280},{"nctId":"NCT02444000","phase":"PHASE3","title":"gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-22","conditions":"Anaplastic Gliomas With 1p/19q Codeletion","enrollment":280},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT07104266","phase":"PHASE2","title":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-08-04","conditions":"Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT00003375","phase":"PHASE2, PHASE3","title":"Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-10","conditions":"Brain and Central Nervous System Tumors","enrollment":370},{"nctId":"NCT01678352","phase":"EARLY_PHASE1","title":"Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas","status":"COMPLETED","sponsor":"Frank Lieberman","startDate":"2012-10","conditions":"High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma","enrollment":19},{"nctId":"NCT02297230","phase":"PHASE1, PHASE2","title":"Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2002-06","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT00002806","phase":"PHASE2","title":"Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1996-07","conditions":"Brain and Central Nervous System Tumors","enrollment":43},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT01339988","phase":"PHASE4","title":"Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2011-06","conditions":"Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Radiotherapy+PCV chemotherapy","genericName":"Radiotherapy+PCV chemotherapy","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Radiotherapy works by damaging the DNA of cancer cells, while PCV chemotherapy targets rapidly dividing cells with a combination of drugs. Used for Glioblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}